The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
The expression of costimulatory molecules such as CD70 or CD80 by gene-modified tumor cells has been shown to enhance the antitumor immune response based mainly on T lymphocytes. However, most human tumors show defects of major histocompatibility complex (MHC) expression, preventing them from being recognized by MHC-restricted T cells. To investigate if coexpression of CD70 and CD80 costimulatory molecules induces comparable antitumor responses in low and high MHC-expressing tumor cells, we used two low immunogenic murine tumor models, the B16.F10 melanoma and the TS/A mammary adenocarcinoma cell lines expressing, respectively, low and high levels of MHC class I molecules. Transfection of both CD70 and CD80 genes resulted in an increased capacity of gene-modified tumor cells to costimulate in vitro the proliferation and cytokine production of optimally activated lymphoid cells. Coexpression of CD70 and CD80 by the two tumor cell lines, TS/A and B16.F10, resulted in both cases in partial regression of subcutaneous tumors. Immunochemical analysis and studies in nude mice showed that, even in the B16.F10 model, T cells had a significant role in the antitumor response induced by combining CD70 and CD80. However, rejection of the CD70/CD80-transfected tumor cells appeared more effective in the MHC class I high TS/A model, leading to a protection against parental tumor cells. B16.F10 and TS/A transfectants were then tested with fibroblasts genetically modified to secrete interleukin-12 (IL-12) as a therapeutic vaccine in mice bearing parental tumors. In the two models tested, the injections of irradiated IL-12 and CD70/CD80 gene-modified cells generated an antitumor response to established tumors leading to the slowing down of the tumor growth rate. Although the mechanisms remain to be defined, these findings suggest that the combination of several immuno-modulatory molecules could provide additional strategies for cancer immuno-gene therapy, even for MHC expression-deficient tumors.
Douin-Echinard
V
V
Laboratoire d'Oncologie Moléculaire et Cellulaire, Institut Claudius Regaud, Toulouse, France.
Bornes
S
S
Rochaix
P
P
Tilkin
A F
AF
Peron
J M
JM
Bonnet
J
J
Favre
G
G
Couderc
B
B
D000818:Animals; D015703:Antigens, CD; D018122:B7-1 Antigen / Q000096:biosynthesis*; D053282:CD27 Ligand; D017931:DNA Primers; D005260:Female; D005434:Flow Cytometry; D015870:Gene Expression; D005805:Genes, MHC Class I / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D016130:Immunophenotyping; D007371:Interferon-gamma / Q000378:metabolism; D018664:Interleukin-12 / Q000378:metabolism; D008325:Mammary Neoplasms, Experimental / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D008546:Melanoma, Experimental / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D008565:Membrane Proteins / Q000096:biosynthesis*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D012190:Retroviridae / Q000235:genetics; D014162:Transfection
D015703:Antigens, CD; D018122:B7-1 Antigen; D053282:CD27 Ligand; C505771:CD70 protein, human; C505772:Cd70 protein, mouse; D017931:DNA Primers; D008565:Membrane Proteins; D018664:Interleukin-12; D007371:Interferon-gamma